N/A
N=399
Surveillance of Ocular Surface Flora (SURFACE)
Cataract
Bottom Line
View on ClinicalTrials.gov: NCT00621933 ↗Enrolled (actual)
399
Serious AEs
—
Results posted
Jul 2012
Primary outcome: Primary: Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid — 51; 48 Percentage of Species
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Oct 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid |
51; 48 | — |
| PRIMARY Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva |
52; 45 | — |
| SECONDARY Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Eyelid |
59; 34 | — |
| SECONDARY Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva |
70; 21 | — |
Summary
Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the treatment and prophylaxis of ocular infections. The present study is set to determine the bacteria present on the ocular surface in patients at the time of cataract surgery and to assess the rate of resistance of ocular isolates to commonly used topical antibiotics.
Eligibility Criteria
Inclusion Criteria
- Scheduled to undergo cataract surgery
- Able to provide written informed consent
Exclusion Criteria
- NSAID in the eye to be swabbed within the past 30 days
- Topical anesthetic, topical antibiotic or antiseptic, or dilating drops in the eye to the swabbed within the past 7 days
- Over-the-counter artificial tear drops or astringent /redness reliever drops (e.g., Visine®, Clear eyes® in the eye to be swabbed on the day of trial
- History of conjunctivitis or any ocular infection within the past 3 months
Data sourced from ClinicalTrials.gov (NCT00621933). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.